

Supplementary Information for

Interception of host fatty acid metabolism by mycobacteria under hypoxia
to suppress anti-TB immunity


Hua Yang^{1#}, Fei Wang^{2#}, Xinya Guo^{1#}, Feng Liu^{1#}, Zhonghua Liu¹, Xiangyang Wu²,
Mengmeng Zhao², Mingtong Ma², Haipeng Liu¹, Lianhua Qin¹, Lin Wang¹, Tianqi
Tang², Wei Sha³, Yang Wang², Jianxia Chen¹, Xiaochen Huang¹, Jie Wang¹, Cheng
Peng², Ruijuan Zheng¹, Fen Tang², Lu Zhang⁴, Chunyan Wu⁵, Stefan H Oehlers⁶,
Zhigang Song⁷, Jialei She⁷, Hua Feng⁸, Xunwei Xie⁹, Baoxue Ge^{1,2*}

Correspondence: gebaoxue@sibs.ac.cn

This PDF file includes:

Figures S1 to S12


Tables S1 to S4



21


22 **Supplementary Fig. S1. Hypoxia induces FadA.** **a** Kyoto Encyclopedia of Genes and
 23 Genomes (KEGG) pathway enrichment of differentially secreted proteins by
 24 comparing hypoxia with aeration. **b-e** Quantitative polymerase chain reaction (qPCR)
 25 analysis of Rv0824c (**b**), Rv0860 (**c**), Rv1094 (**d**), Rv3774 (**e**) mRNA from H37Rv
 26 incubated under aeration and hypoxia for 0, 7 or 14 days *in vitro* (mean \pm s.e.m.). Data
 27 are representative of one experiment with at least three independent biological
 28 replicates; each circle represents one technical repeat. Bar charts show means. **f**
 29 Immunoblot (IB) of cell lysate and culture filtrate from *M. marinum* incubated under
 30 aeration and hypoxia for 0, 3, 7 or 10 days with anti-FadA, anti-ESAT-6 and anti-SigA
 31 antibodies at a 1:1000 dilution. Bars represent densitometric analysis of band intensity.
 32 **g, h** Immunolocalization of FadA in lung granuloma sections from lung cancer patient
 33 (**g**) and whole fish sections of uninfected adult zebrafish (**h**) with anti-FadA polyclonal
 34 antibody at a 1:100 dilution and anti-rabbit secondary antibody labeled with HRP at a
 35 1:200 dilution (scale bar, 100 μ m (top) and 20 μ m (bottom)), compared with anti-ESAT-
 36 6 polyclonal antibody at a 1:200 dilution, isotype polyclonal control antibody at a 1:100
 37 dilution and anti-SigA antibody labeled with HRP at 1:100 dilution (scale bar, 100 μ m

38 (top) and 20 μm (bottom)). Results in **f-h** are representative of three independent
 39 experiments. Two-tailed unpaired Student's *t*-test (**b-e**) was used for statistical analysis.



40
 41 **Supplementary Fig. S2. IB and Growth curve *in vitro* of H37Rv, H37Rv ΔFadA or**
 42 **H37Rv($\Delta\text{FadA}+\text{FadA}$) strains. **a** IB of cell lysate and culture filtrate of H37Rv,**
 43 **H37Rv ΔFadA or H37Rv($\Delta\text{FadA}+\text{FadA}$) strains with anti-FadA, anti-ESAT-6 and anti-**
 44 **SigA antibodies at a 1:1000 dilution. Bars represent densitometric analysis of band**
 45 **intensity. Results are representative of three independent experiments. **b** Growth curve**
 46 ***in vitro* of H37Rv, H37Rv ΔFadA or H37Rv($\Delta\text{FadA}+\text{FadA}$) strains under aeration or**
 47 **hypoxia. The strains were grown to mid-log phase and the growth curve was measured**
 48 **using a Bioscreen Growth Curve Instrument. Hypoxic conditions were established by**
 49 **covering bacterial suspensions with paraffin oil. The optical density was measured at**
 50 **an absorbance of 590 nm every day. Cultures of H37Rv, H37Rv ΔFadA or**
 51 **H37Rv($\Delta\text{FadA}+\text{FadA}$) strains were grown at 37 °C for 14 days. Data are representative**
 52 **of one experiment with at least three independent biological replicates.**

53
 54
 55
 56
 57
 58
 59
 60



61

62 **Supplementary Fig. S3. Pathology assessment in lung sections of C3HeB/FeJ mice**
63 **infected with H37Rv, H37RvΔFadA or H37Rv(ΔFadA+FadA) strains.** a-c Six-
64 week-old female C3HeB/FeJ mice were aerosol-infected with roughly 200 colony-
65 forming unit (CFU) per mouse of H37Rv, H37RvΔFadA or H37Rv(ΔFadA+FadA)
66 strains for 1 day or 4 weeks. Histopathology was assessed in lung sections by bacterial
67 CFU counting (**a**; mean ± s.e.m. of n=3 mice infected for 1 day or n=5 mice infected
68 for 4 weeks), haematoxylin and eosin (H&E) and acid-fast staining from lungs of mice
69 infected for 4 weeks (**b**; representative of one experiment with at least three
70 independent replicates; scale bar, 100 μm (top) and 20 μm (bottom)) and histologic
71 score (**c**). One-way ANOVA with Bonferroni's multiple comparisons test (**a, c**) was used
72 for statistical analysis.

73

74

75

76

77

78


79

80

81

82

83



84

85 **Supplementary Fig. S4.** qPCR analysis of *Ill1b* (a), *Ill2 p40* (b) and *Tnfα* (c) mRNA
 86 from peritoneal macrophages infected with H37Rv, H37RvΔFadA or
 87 H37Rv(ΔFadA+FadA) strains for 4h (MOI=1) (mean ± s.e.m.). Data are representative
 88 of one experiment with at least three independent biological replicates; each circle
 89 represents one technical repeat. Bar charts show means. One-way ANOVA with
 90 Bonferroni's multiple comparisons test (a-c) was used for statistical analysis.

91

92

93

94

95

96

97

98

99

100

101


102

103

104

105

il6 ENSDARG00000102318



```

il6+/+  ATG CCA TCC GCT ----- CTG ATG GCC AGA GAT CTG TAC AAG GAC GTG ----- AAG AAC TAA
          M  P  S  A  ----- W  H  L  M  A  R  D  L  Y  K  ----- D  K  N  *  ◀ 231aa

il612d2i ATG CCA TCC GCT ----- CTG ATG GCC AGA GAT --- --- --- --- GAG TGA AGA    -10 bp (-12 bp, +2 bp)
          M  P  S  A  ----- W  H  L  M  A                               R  D  E  *  ◀ 65aa

il620dl  ATG CCA TCC GCT ----- CTG ATG GCC AGA GAT --- --- --- --- --- --- --- --- ACT CAG AGA CGA GCA GTT TGA GAG    -20 bp
          M  P  S  A  ----- W  H  L  M  A                               R  D  T  Q  R  R  A  V  *  ◀ 70aa
  
```


106

107 **Supplementary Fig. S5. Generation of *il6*^{12d2i} and *il6*^{20dl} mutant zebrafish lines**
 108 **using CRISPR-Cas9 mutagenesis.** The Cas9/gRNA system was employed to generate
 109 IL-6 knockout zebrafish, which was constructed by the China Zebrafish Resource
 110 Center (CZRC) as described previously. An appropriate guide RNA (gRNA) target site
 111 was identified in the second exon of *il6*. gRNA target sites were sequenced from F₁ -
 112 generation mutant zebrafish and two frameshift mutations (*il6*^{12d2i}: -10 bp deletion and
 113 +2 bp insertion; and *il6*^{20dl}: -20bp deletion) detected, leading to truncated protein
 114 products of 65 and 70 amino acids, respectively.

115


116

117



118

119 **Supplementary Fig. S6. Pathology assessment in lung sections of C3HeB/FeJ mice**
 120 **infected with H37Rv, H37Rv Δ FadA or H37Rv(Δ FadA+FadA) strains treated with**
 121 **neutralizing anti-IL-6 mAb. a** Diagram showing the procedure for H37Rv,
 122 H37Rv Δ FadA or H37Rv(Δ FadA+FadA) strains infected C3HeB/FeJ mice treated with
 123 a neutralizing anti-IL-6 or an isotype-matched control mAb. **b-d** Six-week-old female
 124 C3HeB/FeJ mice were aerosol-infected with roughly 200 CFU/mouse of H37Rv,
 125 H37Rv Δ FadA or H37Rv(Δ FadA+FadA) strains. At 1-week post infection, mice
 126 received 0.3 mg of anti-IL-6 mAb (BioXcell) or isotype-matched control Ab (rat IgG1)
 127 intranasally once 1 week for up to 4 weeks. Histopathology was assessed in lung
 128 sections by bacterial CFU counting (**b**; mean \pm s.e.m. of n=5 mice infected for 4 weeks),
 129 H&E and acid-fast staining from lungs of mice infected for 4 weeks (**c**; representative
 130 of one experiment with at least three independent replicates; scale bar, 100 μ m (top
 131 and 20 μ m (bottom)) and histologic score (**d**). One-way ANOVA with Bonferroni's
 132 multiple comparisons test (**b, d**) was used for statistical analysis.
 133



134

135 **Supplementary Fig. S7. FadA suppresses Il-6 through H3K9Ac. a, b** qPCR analysis
 136 of *Il12b*(a) or *Tnfa*(b) mRNA from control or histone deacetylase (HDAC) 1-3 inhibitor
 137 CI-994-pretreated peritoneal macrophages infected with H37Rv, H37RvΔFadA or
 138 H37Rv(ΔFadA+FadA) strains for 4h (MOI=1) (mean ± s.e.m.). Data in **a-b** represent
 139 one experiment with at least three independent replicates. Two-way ANOVA with
 140 Bonferroni's multiple comparisons test (**a-b**) was used for statistical analysis (ns, not
 141 significant; **** $P < 0.0001$).

142

143

144


145

146

147

148

149



150

151 **Supplementary Fig. S8. FadA downregulates the general H3K9Ac enrichment.**

152 ChIP-seq analysis of histone H3 acetylation at the lysine 9 residue (H3K9Ac) of
 153 peritoneal macrophage infected with H37Rv or H37RvΔFadA strains (MOI=1) for 4h
 154 with SimpleChIP Enzymatic Chromatin IP Kit and the Illumina Hiseq Xten platforms
 155 at the CAS-MPG Partner Institute for Computational Biology Omics Core.

156

157

158

159

160

161

162

163

164

165


166

167

168

169

170




171

172 **Supplementary Fig. S9. IB of various FadA mutants in *M. tuberculosis* and *M.***
 173 ***marinum* strains. a** Analysis of the purified FadA recombinant protein and its
 174 derivative mutant protein. Construction and purification of FadA recombinant protein
 175 and its derivative mutants were performed as described before and analyzed by Dodecyl
 176 sulfate, sodium salt -Polyacrylamide gel electrophoresis (SDS-PAGE). M. PageRuler

177 prestained protein ladder (Fermentas); lane 1. the purified FadA protein with an
178 expected molecular weight of 43.97 kDa; lane 2. the purified FadA(H359A) protein
179 with an expected molecular weight of 43.90 kDa; lane 3. the purified FadA(C389A)
180 protein with an expected molecular weight of 43.94 kDa. **b** IB of lysate of H37Rv,
181 H37Rv Δ FadA, H37Rv(Δ FadA+FadA), H37Rv(Δ FadA+FadA(H359A)), and
182 H37Rv(Δ FadA+FadA(C389A)) strains with anti-FadA antibody and control anti-SigA
183 antibody at a 1:1000 dilution. **c** IB of lysate of WT, Δ FadA, Δ FadA+FadA,
184 Δ FadA+FadA(H373A), and Δ FadA+FadA(C403A) *M. marinum* strains with anti-FadA
185 antibody and control anti-SigA antibody at a 1:1000 dilution. **d** IB of culture filtrate
186 and cell lysate from H37Rv, H37Rv Δ FadA, H37Rv(Δ FadA+FadA),
187 H37Rv(Δ FadA+FadA(H359A)), and H37Rv(Δ FadA+FadA(C389A)) strains incubated
188 under aeration and hypoxia for 7 days with anti-FadA, anti-ESAT-6 and anti-SigA
189 antibodies at a 1:1000 dilution. **e** IB of culture filtrate and cell lysate from WT, Δ FadA,
190 Δ FadA+FadA, Δ FadA+FadA(H373A), and Δ FadA+FadA(C403A) *M. marinum* strains
191 incubated under aeration and hypoxia for 7 days with anti-FadA, anti-ESAT-6 and anti-
192 SigA antibodies at a 1:1000 dilution. Bars represent densitometric analysis of band
193 intensity. Results are representative of three independent experiments.

194
195
196
197
198
199
200
201
202
203
204
205
206



207

208 **Supplementary Fig. S10. FadA functions through its acetyltransferase activity. a**

209 qPCR analysis of *Il6* mRNA from control or HDAC 1-3 inhibitor CI-994-pretreated

210 peritoneal macrophages infected with H37Rv, H37Rv Δ FadA, H37Rv(Δ FadA+FadA),

211 H37Rv(Δ FadA+FadA(H359A)), and H37Rv(Δ FadA+FadA(C389A)) strains for 4h

212 (MOI=1) (mean \pm s.e.m.). **b** qPCR analysis of *Il6* mRNA from control or ATP-citrate

213 lyase (ACL) inhibitor BMS-303141-pretreated peritoneal macrophages infected with


214 H37Rv, H37Rv Δ FadA, H37Rv(Δ FadA+FadA), H37Rv(Δ FadA+FadA(H359A)), and

215 H37Rv(Δ FadA+FadA(C389A)) strains for 4h (MOI=1) (mean \pm s.e.m.). Data in **a**, **b**

216 are representative of one experiment with at least three independent biological

217 replicates; each circle represents one technical repeat. **c** qPCR analysis of *Il6* mRNA

218 from adult zebrafish intraperitoneally infected with roughly 200 CFU of WT, Δ FadA,
219 Δ FadA+FadA, Δ FadA+FadA(H373A), Δ FadA+FadA(C403A) *M. marinum* strains for
220 14 days (mean \pm s.e.m. of n=5). **d-f** Adult zebrafish were intraperitoneally infected with
221 roughly 200 CFUs of WT, Δ FadA, Δ FadA+FadA, Δ FadA+FadA(H373A), and
222 Δ FadA+FadA(C403A) *M. marinum* strains for 14 days. Histopathology was assessed
223 in the whole fish by comparison of granulomas between different *M. marinum*-infected
224 adult zebrafish scored for *M. marinum* burden as less than 10 or 10 or more bacteria
225 (**d**), or percentage of necrotic granulomas in each fish (**e**) and H&E or acid-fast staining
226 (**f**; representative of one experiment with at least three independent replicates; scale bar,
227 100 μ m (top) and 20 μ m (bottom)). “n” in **g, h** was the total number of granulomas for
228 each strain infected fish. Total number of zebrafish analyzed: 5 (WT), 5 (Δ FadA), 5
229 (Δ FadA+FadA), 5 (Δ FadA+FadA(H373A)), 5 (Δ FadA+ FadA(C403A)). Data in **c-f**
230 represent one experiment with at least three independent replicates. One-way (**c**) or
231 two-way (**a, b**) ANOVA with Bonferroni's multiple comparisons test and Fisher's exact
232 test (**d, e**) were used for statistical analysis (ns, not significant; **** $P < 0.0001$).
233



234

235 **Supplementary Fig. S11. Pathology assessment in adult zebrafish infected with *M.***

236 ***marinum* strains treated with sodium acetate (NaAc).** Adult zebrafish were

237 intraperitoneally infected with roughly 200 CFU of WT or Δ FadA *M. marinum* strains

238 for 14 days. NaAc was injected intraperitoneally to a final concentration of 2 mM


239 immediately after infection and reinjected every 3 days. Histopathology was assessed

240 in the whole fish by H&E or acid-fast staining (representative of one experiment with

241 at least three independent replicates; scale bar, 100 μ m (top) and 20 μ m (bottom)).

242

243



244

245 **Supplementary Fig. S12. An interception model to host fatty acid metabolism by**
 246 **mycobacteria under hypoxia to suppress anti-TB immunity.** *M. tuberculosis* utilizes
 247 numerous strategies for immune evasion. Intriguingly, mycobacteria under hypoxia
 248 markedly secrete the protein FadA, which acts as an acetyltransferase that converts host
 249 acetyl-CoA to acetoacetyl-CoA to reduce the host acetyl-CoA level and then suppress
 250 the histone H3K9 acetylation-mediated expression of *Il6*, thus promoting the
 251 progression of granuloma. Moreover, supplementation of acetate increases the acetyl-
 252 CoA level and inhibits the enhancement effect of FadA on the mycobacterial growth
 253 and the progression of granuloma.

Supplementary Table S1. Upregulated secreted proteins of H37Rv under hypoxia

| Gene ID | Protein | Protein description | Ratio (Hypo/Aero) | <i>p</i> -value |
|---------|---------|---|-------------------|-----------------|
| Rv2059 | O07257 | Zinc/manganese transporter substrate-binding protein | 1.855 | 0.00218 |
| Rv0824 | I6XWD0 | Acyl-[acyl-carrier-protein] desaturase | 1.724 | 0.00001 |
| Rv2031c | I6Y869 | Heat shock protein hspX | 1.723 | 0.00000 |
| Rv0467 | I6Y7W3 | Isocitrate lyase | 1.661 | 0.00000 |
| Rv3418 | I6Y3F9 | 10 kDa chaperonin | 1.618 | 0.00000 |
| Rv1133c | I6Y5P6 | 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase | 1.600 | 0.00000 |
| Rv1837c | I6X2F8 | Malate synthase G | 1.582 | 0.00011 |
| | | 3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase/3- | | |
| Rv0860 | I6Y8Y4 | hydroxybutyryl-CoA epimerase | 1.576 | 0.00000 |
| Rv0859 | I6X9Z1 | Acetyl-CoA C-acetyltransferase | 1.565 | 0.01039 |
| Rv0670 | I6Y4E3 | Probable endonuclease 4 | 1.526 | 0.00162 |
| Rv3042 | I6X638 | Phosphoserine phosphatase | 1.512 | 0.04787 |
| Rv1094 | I6Y5K6 | Acyl-[acyl-carrier-protein] desaturase | 1.497 | 0.00000 |
| Rv2391 | I6YDA2 | Sulfite reductase [ferredoxin] | 1.464 | 0.04162 |
| Rv0251c | O53673 | Heat shock protein hsp | 1.457 | 0.03051 |
| Rv2996 | I6X5Z2 | D-3-phosphoglycerate dehydrogenase | 1.445 | 0.00000 |
| Rv2711 | I6XF43 | Iron-dependent repressor IdeR | 1.440 | 0.00551 |

| | | | | |
|---------|--------|---|-------|---------|
| Rv3774 | P75019 | Enoyl-CoA hydratase | 1.387 | 0.00081 |
| Rv3841 | I6YD59 | Bacterioferritin bfrB | 1.368 | 0.00000 |
| Rv0815c | I6X9V7 | Sulfurtransferase | 1.366 | 0.00000 |
| Rv2626c | I6Y193 | Hypoxic response protein 1 | 1.332 | 0.00390 |
| Rv0211 | I6Y334 | Phosphoenolpyruvate carboxykinase [GTP] | 1.324 | 0.00851 |
| Rv0475 | I6X969 | Heparin-binding hemagglutinin | 1.311 | 0.00002 |

Supplementary Table S2. Downregulated secreted proteins of H37Rv under hypoxia

| Gene ID | Protein | Protein description | Ratio (Hypo/Aero) | <i>p</i> -value |
|---------|---------|---|-------------------|-----------------|
| Rv2346c | I6XE37 | ESAT-6-like protein esxN | 0.244 | 0.02910 |
| Rv1793 | I6Y7I0 | ESAT-6-like protein esxN | 0.253 | 0.03389 |
| Rv3616c | I6XHT2 | ESX-1 secretion-associated protein EspA | 0.274 | 0.01934 |
| Rv3615c | I6Y444 | ESX-1 secretion-associated protein EspC | 0.322 | 0.01972 |
| Rv0379 | I6X919 | Preprotein translocase subunit secE2 | 0.391 | 0.00126 |
| Rv1197 | I6X0L2 | ESAT-6-like protein esxK | 0.396 | 0.00002 |
| Rv1813c | I6Y7J9 | Uncharacterized protein | 0.419 | 0.03948 |
| Rv2226 | I6X3M7 | Uncharacterized protein | 0.534 | 0.01440 |
| Rv3801c | I6YD25 | Fatty acid CoA ligase FadD32 | 0.554 | 0.01320 |
| Rv3874 | B5TV88 | 10 kDa culture filtrate protein | 0.574 | 0.00035 |
| Rv0088 | I6X8H2 | Uncharacterized protein | 0.590 | 0.00646 |
| Rv0707 | I6Y8I3 | 30S ribosomal protein S3 | 0.609 | 0.02991 |
| Rv3800c | I6X8D2 | Polyketide synthase 13 | 0.613 | 0.00000 |
| Rv0721 | I6X9M1 | 30S ribosomal protein S5 | 0.630 | 0.00024 |
| Rv0685 | I6Y4F5 | Elongation factor Tu | 0.643 | 0.00002 |
| Rv1392 | I6X149 | S-adenosylmethionine synthase | 0.656 | 0.03341 |
| Rv0928 | I6XWK9 | Phosphate-binding protein PstS | 0.657 | 0.00151 |

| | | | | |
|---------|--------|--|-------|---------|
| Rv2984 | A5YKM2 | Polyphosphate kinase | 0.662 | 0.02981 |
| Rv3597c | I6X7R6 | Protein lsr2 | 0.671 | 0.00540 |
| Rv2909c | I6X5P6 | 30S ribosomal protein S16 | 0.685 | 0.01179 |
| Rv3596c | I6YGL7 | ATP-dependent Clp protease ATP-binding subunit ClpC | 0.695 | 0.02442 |
| | | 2-oxoglutarate dehydrogenase, E2 component, dihydrolipoamide | | |
| Rv2215 | I6XDT2 | succinyltransferase | 0.708 | 0.00048 |
| Rv2908c | I6YEP3 | UPF0109 protein RVBD_2908c | 0.713 | 0.00617 |
| Rv3458c | I6X7D0 | 30S ribosomal protein S4 | 0.722 | 0.02838 |
| Rv3859c | I6Y4Q0 | Glutamate synthase (NADPH/NADH) large chain | 0.729 | 0.03078 |
| Rv1876 | I6YBU4 | Bacterioferritin | 0.732 | 0.01145 |
| Rv0066c | O53611 | Isocitrate dehydrogenase, NADP-dependent | 0.733 | 0.00066 |
| Rv0667 | I6XVX4 | DNA-directed RNA polymerase subunit beta | 0.748 | 0.00013 |
| Rv1060 | O53408 | Uncharacterized protein | 0.761 | 0.03443 |

Supplementary Table S3 Bacterial strains and plasmids used in this study.

| Name | Description | Reference |
|---|--|-----------------------|
| Strains | | |
| <i>E. coli</i> DH5 α | F- 80 <i>lacZ</i> M15 (<i>lacZYA</i> – <i>argF</i>)U169 <i>eoR recA1 endA1 hsdR17 phoA supE44-thi-1 gyrA96 relA1</i> | Laboratory stock |
| <i>E. coli</i> BL21 | F- <i>ompT gal dcm lon hsdSB</i> (rB- mB-) λ (DE3 [<i>lacI lacUV5</i> -T7 gene 1 <i>ind1 sam7 nin5</i>]) | Laboratory stock |
| <i>M. smegmatis mc</i> ² 155 | wild type <i>M. smegmatis</i> reference strain | Laboratory stock |
| <i>M. tuberculosis</i> H37Rv | wild type <i>M. tuberculosis</i> virulent reference strain | Laboratory stock |
| <i>M. tuberculosis</i> H37Ra | wild type <i>M. tuberculosis</i> avirulent reference strain | Laboratory stock |
| <i>M. marinum</i> Aronson (BAA-535) | wild type <i>M. marinum</i> reference strain | Gift from Dr. Zhang L |
| H37Rv Δ FadA | <i>M. tuberculosis</i> H ₃₇ Rv Δ FadA :: <i>hyg</i> | This study |

| | | |
|--|--|----------------------|
| H37Rv(Δ FadA+FadA) | <i>M. tuberculosis</i> H ₃₇ Rv Δ FadA+FadA | This study |
| H37Rv(Δ FadA+FadA(H359A)) | <i>M. tuberculosis</i> H ₃₇ Rv Δ FadA+FadA (H359A) | This study |
| H37Rv(Δ FadA+FadA(C389A)) | <i>M. tuberculosis</i> H ₃₇ Rv Δ FadA+FadA (C389A) | This study |
| Δ FadA (<i>M. marinum</i>) | <i>M. marinum</i> Aronson Δ FadA ::hyg | This study |
| Δ FadA +FadA (<i>M. marinum</i>) | <i>M. marinum</i> Aronson Δ FadA +FadA | This study |
| Δ FadA +FadA(H373A) (<i>M. marinum</i>) | <i>M. marinum</i> Aronson Δ FadA +FadA (H373A) | This study |
| Δ FadA +FadA(C403A) (<i>M. marinum</i>) | <i>M. marinum</i> Aronson Δ FadA +FadA (C403A) | This study |
| Vector Plasmid | | |
| pET28a | Expression vector | Laboratory stock |
| pVV16 | <i>E. coli</i> / Mycobacterium shuttle plasmid | Laboratory stock |
| pYUB854 | Cosmid vector containing allelic exchange substrates | Gift from Dr. Lyu LD |

| | | |
|-------------------------|---|----------------------|
| phAE87 | Temperature-sensitive shuttle phasmid to generate a specialized transducing mycobacteriophage | Gift from Dr. Lyu LD |
| pET28a-FadA | Kan ^R , pET28a harboring Rv0859 | This study |
| pET28a-FadA(H359A) | Kan ^R , pET28a harboring Rv0859(H359A) | This study |
| pET28a-FadA(C389A) | Kan ^R , pET28a harboring Rv0859(C389A) | This study |
| pVV16-Rv0859 | Kan ^R , Hyg ^R , pVV16 harboring Rv0859 | This study |
| pVV16-Rv0859(H359A) | Kan ^R , Hyg ^R , pVV16 harboring Rv0859(H359A) | This study |
| pVV16-Rv0859(C389A) | Kan ^R , Hyg ^R , pVV16 harboring Rv0859(C389A) | This study |
| pVV16- MMAR_4677 | Kan ^R , Hyg ^R , pVV16 harboring MMAR_4677 | This study |
| pVV16-MMAR_4677(H373A) | Kan ^R , Hyg ^R , pVV16 harboring MMAR_4677(H373A) | This study |
| pVV16- MMAR_4677(C403A) | Kan ^R , Hyg ^R , pVV16 harboring MMAR_4677(C403A) | This study |

Supplementary Table S4 Primers used in this study.

| Primer name | Sequence (5'-3') |
|--------------------|----------------------------------|
| mIL-1 β -F | AGAAACAGTCCAGCCCATAC |
| mIL-1 β -R | CTGGTACATCAGCACCTCAC |
| mIL-6-F | TCCAGTTGCCTTCTTGGGAC |
| mIL-6-R | GTGTAATTAAGCCTCCGACTTG |
| mIL-12P40-F | GAGCACTCCCCATTCTACT |
| mIL-12P40-R | CCCTCCTCTGTCTCCTTCAT |
| mTNF- α -F | TTCTGTCTACTGAACTTCGGGGTGATCGGTCC |
| mTNF- α -R | GTATGAGATAGCAAATCGGCTGACGGTGTGGG |
| mGAPDH-F | CCCACTAACATCAAATGGGG |
| mGAPDH-R | CCTTCCACAATGCCAAAGTT |
| pVV16-Rv0859-F | GGAATCACTTCCATatgtccgaagaagcc |
| pVV16-Rv0859-R | GTGGTGGTGAAGCTTaaccctctcgatgatc |
| pVV16-Mm4677-F | GGAATCACTTCCATatgacggatctgaac |
| pVV16-Mm4677-R | GTGGTGGTGAAGCTTaaccctctcgatgatc |
| pET28a-Rv0859-F | ATGGGTCGCGGATCCatgtccgaagaagcc |
| pET28a-Rv0859-R | GTGGTGGTGTCTCGAGaaccctctcgatgatc |
| Rv0824c-RTF | TTGAACCGGTCGTCGAGAAG |
| Rv0824c-RTR | ACCTGGGCGACATCAGAAAG |

| | |
|----------------------------|--------------------------|
| Rv0860-RTF | GGCGAGATCGAAGACATCGT |
| Rv0860-RTR | AAAGTCTTCCTGCCGCTTGA |
| Rv1094-RTF | AGGACGTTCGAGTCCAACAC |
| Rv1094-RTR | AGAACGCCATGTACACCAGG |
| Rv3774-RTF | CAAGCTAGCGATTGTTGCCG |
| Rv3774-RTR | AGCGCGAGTTCTCGTAGATG |
| Rv0859-RTF | TTCCCGACGAGAAGCTCAAC |
| Rv0859-RTR | GATGCACAGCGTGATGAGTG |
| mIL-6-Intron-F | TCTGGCGGAGCTATTGAGAC |
| mIL-6-Intron-R | GATGGAAGTCTCCTGCGTGG |
| 16sRNA-F | CCGCGGCCTATCAGCTTGTTGGT |
| 16sRNA-R | GTAGTTGGCCGGTGCTTCTTCTCC |
| β -actin-zebrafish-F | ATGGATGAGGAAATCGCTGCC |
| β -actin-zebrafish-R | CTCCCTGATGTCTGGGTCGTC |
| IL6-zebrafish-F | TGCTACACTGGCTACACTCTT |
| IL6-zebrafish-R | CACATCCTGAACTTCGTCTCC |